Biomarin
Home
Contact Us
Site Map
ABOUT US
Message from Management
Leadership Team
Management Team
Board of Directors
Scientific Advisory Board
History
PRODUCTS
Naglazyme
®
Aldurazyme
®
Kuvan
®
Firdapse
™
PIPELINE
Clinical Trials
BUSINESS
Manufacturing
Sales & Marketing
BioMarin Europe Ltd./BioMarin Latin America
Partnerships
BioMarin/Genzyme
Merck Serono
INVESTORS
Financial Information
SEC Filings
Corporate Governance
Investors’ Kit
Calendar of Events
PATIENTS/PHYSICIANS
Diseases
Lysosomal Storage Disorders
MPS I
MPS VI
PKU
LEMS
Patient Stories
AnnaBelle
Julie
Gina
Lauren
Liam
Kendra
Shafon
Tyler
Semih & Selim
Resource Library
Patient-Organizations
Professional Organizations
Publications
BioMarin Patient/Physician Support
CAREERS
Benefits
Career Opportunities
MEDIA
Press Releases
Company Overview
Company History
Site Map
About Us
Message from Management
Leadership Team
Management Team
Board of Directors
Scientific Advisory Board
History
Products
Naglazyme®
Aldurazyme®
Kuvan®
Firdapse™
Pipeline
Pipeline Overview
GALNS for MPS IVA (Morquio A Syndrome)
PEG-PAL for PKU
BMN-701: IGF2-GAA for Pompe Disease
BMN-673: PARP Inhibitor for Genetically Defined Cancers
BMN-111: CNP for Achondroplasia
Clinical Trials
Business
Manufacturing
Sales and Marketing
BioMarin Europe Ltd./BioMarin Latin America
Partnerships
BioMarin/Genzyme
BioMarin/Merck Serono
Investors
Financial Information
SEC Filings
Corporate Governance
Investors’ Kit
Calendar of Events
Patients / Physicians
Diseases
Lysosomal Storage Disorders
MPS I
MPS VI
PKU
LEMS
Patient Stories
AnnaBelle
Julie
Gina
Lauren
Liam
Kendra
Shafon
Tyler
Semih & Selim
Resource Library
Patient-Organizations
Professional Organizations
Publications
BioMarin Patient/Physician Support
Careers
Benefits
Career Opportunities
Media
Press Releases
Company Overview
Company History
Contact Us
Directions to BioMarin Headquarters
Glossary
Legal Notice
Site Map
Search
